These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 14767280)

  • 21. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ; Chen J; Stenger A; Matzkin H
    Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Feasibility and toxicity of a single fraction high-dose-rate brachytherapy followed by a course of EBRT for localized prostate cancer: a retrospective study. The Polyclinique Courlancy experience].
    Mallet F; Wdowczyk D; Bruna A; Villena P; Herard A; Amory JP; Joffroy P; Pangrazzi T
    Cancer Radiother; 2010 Jan; 14(1):11-8. PubMed ID: 20005765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose-rate brachytherapy for large prostate volumes (> or =50cc)-Uncompromised dosimetric coverage and acceptable toxicity.
    Monroe AT; Faricy PO; Jennings SB; Biggers RD; Gibbs GL; Peddada AV
    Brachytherapy; 2008; 7(1):7-11. PubMed ID: 18299109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
    Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
    Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
    Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re: Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer.
    Deger S
    J Urol; 2004 Sep; 172(3):1198; author reply 1198. PubMed ID: 15311075
    [No Abstract]   [Full Text] [Related]  

  • 31. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study.
    Vargas CE; Martinez AA; Boike TP; Spencer W; Goldstein N; Gustafson GS; Krauss DJ; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):416-23. PubMed ID: 16879929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.
    Phan TP; Syed AM; Puthawala A; Sharma A; Khan F
    J Urol; 2007 Jan; 177(1):123-7; discussion 127. PubMed ID: 17162020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan.
    Chen YC; Chuang CK; Hsieh ML; Chen WC; Fan KH; Yeh CY; Lee CC; Hong JH
    Urology; 2007 Jul; 70(1):101-5. PubMed ID: 17656217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.
    Jabbari S; Hsu IC; Kawakami J; Weinberg VK; Speight JL; Gottschalk AR; Roach M; Shinohara K
    Brachytherapy; 2009; 8(4):339-44. PubMed ID: 19428310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
    Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
    Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High dose rate and external beam radiotherapy in locally advanced prostate cancer.
    Viani GA; Pellizzon AC; Guimarães FS; Jacinto AA; dos Santos Novaes PE; Salvajoli JV
    Am J Clin Oncol; 2009 Apr; 32(2):187-90. PubMed ID: 19307949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
    Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
    Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
    Ghadjar P; Keller T; Rentsch CA; Isaak B; Behrensmeier F; Stroux A; Thalmann GN; Aebersold DM
    Brachytherapy; 2009; 8(1):45-51. PubMed ID: 19038584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.
    Hsu IC; Cabrera AR; Weinberg V; Speight J; Gottschalk AR; Roach M; Shinohara K
    Brachytherapy; 2005; 4(3):202-6. PubMed ID: 16182220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
    Morton G; Loblaw A; Cheung P; Szumacher E; Chahal M; Danjoux C; Chung HT; Deabreu A; Mamedov A; Zhang L; Sankreacha R; Vigneault E; Springer C
    Radiother Oncol; 2011 Sep; 100(3):463-7. PubMed ID: 21924511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.